Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate

J T van Leeuwen1, A J Smit, J F May

  • 1Department of Internal Medicine, Groningen University Hospital, The Netherlands.

Insights

Lisinopril significantly reduced left ventricular mass index in hypertensive patients, while both lisinopril and diltiazem improved diastolic filling. Lisinopril also demonstrated superior 24-hour blood pressure control compared to diltiazem.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension leads to left ventricular (LV) remodeling, including increased LV mass and diastolic dysfunction.
  • Effective antihypertensive treatment is crucial for improving cardiac structure and function.

Purpose of the Study:

  • To compare the effects of diltiazem and lisinopril on LV mass and diastolic filling in untreated hypertensive patients.
  • To assess the impact of these treatments on office and ambulatory blood pressure.

Main Methods:

  • A 6-month randomized study involving 36 hypertensive patients.
  • Echocardiography and pulsed Doppler were used to measure LV mass and diastolic filling parameters.
  • Office and 24-hour ambulatory blood pressure monitoring were conducted.

Main Results:

  • Lisinopril significantly decreased LV mass index compared to diltiazem (p < 0.05).
  • Both drugs improved diastolic filling parameters, with no significant inter-group difference.
  • Lisinopril showed greater reductions in daytime and nighttime ambulatory blood pressure compared to diltiazem (p < 0.05).

Conclusions:

  • Lisinopril is effective in reducing LV mass in hypertensive patients.
  • Both diltiazem and lisinopril improve diastolic function, but lisinopril offers better 24-hour blood pressure control.
  • Improvements in diastolic filling may be influenced by factors beyond LV mass reduction.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...